Antios Therapeutics B轮融资筹集9600万美元

StephenW

Antios Therapeutics Raises $96 Million in a Series B Financing

Published: Apr 12, 2021

Funding will support the Phase 2 clinical program of ATI-2173 in HBV

Soleus Capital led the round with new major investors RA Capital Management, Adage Capital Management LP, Pontifax and Aisling Capital as well as Altium Capital, Amzak Health, Granite Point Capital Management, LP, and LifeSci Venture Partners and participating existing investors Lumira Ventures, Cam Capital, Delos Capital, Domain Associates and Sixty Degree Capital

MENDHAM, N.J., April 12, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. (“Antios”) today announced the successful completion of a $96 million Series B financing. The proceeds from this financing will support the ongoing Phase 2 clinical program which is evaluating the potential for the Company’s lead clinical candidate, ATI-2173, to be a backbone of a once-daily curative regimen for chronic hepatitis B. ATI-2173 is a novel, orally administered, liver-targeted Active Site Polymerase Inhibitor Nucleotide (ASPIN) that can shut down HBV polymerase activity and viral replication.

The financing was led by Soleus Capital with participation from new major investors RA Capital Management, Adage Capital Management LP, Pontifax and Aisling Capital as well as other healthcare focused funds, Altium Capital, Amzak Health, Granite Point Capital Management, LP, and LifeSci Venture Partners and participation from all of the original Series A investors including Lumira Ventures, CAM Capital, Delos Capital, Domain Associates and Sixty Degree Capital. David Canner, Partner at Soleus Capital and Iyona Rajkomar, MBBS, CFA, Partner at Pontifax, are joining the Board of Directors.

“ATI-2173 has already demonstrated potent on-treatment and durable off-treatment effects in our Phase 1b study in patients with chronic hepatitis B,” said Greg Mayes, Chief Executive Officer of Antios. “Those results will be presented at an upcoming major medical conference. With this financing we are now well positioned to continue to highlight how ATI-2173 may become the backbone of a curative regimen for HBV which remains a significant unmet global public health need. We look forward to working with new and existing investors to advance ATI-2173 forward in development.”

Guy Levy, Chief Investment Officer of Soleus Capital said, “Despite significant progress in recent years, HBV remains an area of high unmet medical need. Given the mechanistic rationale and impressive early data, we believe ATI-2173 could play an essential role in developing curative regimens for the millions of people suffering from chronic HBV infection. We are excited to partner with the experienced team at Antios to help bring this therapy to patients.”

About ATI-2173
ATI-2173 is a novel, orally administered, liver-targeted Active Site Polymerase Inhibitor Nucleotide (ASPIN) molecule designed to deliver the 5’-monophosphate of clevudine to the liver. This L-nucleoside’s active 5’-triphosphate has unique antiviral properties as a non-competitive, non-chain terminating HBV polymerase inhibitor that distorts the active site of HBV polymerase resulting in potent HBV antiviral activity and extended off-treatment suppression of HBV DNA. ATI-2173 targets the liver, delivering high levels of the unique 5’- triphosphate while limiting systemic exposure to the parent L-nucleoside. ATI-2173 has the potential to become an integral part of a curative combination regimen for chronic hepatitis B.

About Antios Therapeutics Inc.
Antios Therapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases. Antios is currently developing ATI-2173, aiming to provide chronic hepatitis B infected patients with a curative combination regimen.

CONTACTS

Investors:
Lee Roth
Burns McClellan
[email protected]
+1 (212) 300-8331

Media:
Ryo Imai / Robert Flamm, Ph.D.
Burns McClellan
[email protected] / [email protected]
+1 (212) 300-8315 / +1 (212) 300-8364

StephenW

Antios Therapeutics B轮融资筹集9600万美元

发行时间：2021年4月12日

资金将支持ATI-2173乙肝病毒2期临床计划

Soleus Capital与新的主要投资者RA Capital Management，Adage Capital Management LP，Pontifax和Aisling Capital以及Altium Capital，Amzak Health，Granite Point Capital Management，LP和LifeSci Venture Partners以及参与的现有投资者Lumira Ventures，Cam一起领导了本轮融资资本，德洛斯资本，域名合伙人和六十度资本

2021年4月12日，新泽西州曼德姆市（GLOBE NEWSWIRE）-Antios Therapeutics，Inc.（以下简称“ Antios”）今天宣布成功完成9600万美元的B轮融资。此次融资的收益将支持正在进行的第二阶段临床计划，该计划正在评估该公司的主要临床候选药物ATI-2173成为每日一次慢性乙型肝炎治疗方案的骨干的潜力。ATI-2173是新型的，口服给药的，以肝脏为靶点的活性位点聚合酶抑制剂核苷酸（ASPIN），可以关闭HBV聚合酶活性和病毒复制。

融资由Soleus Capital牵头，新的主要投资者RA Capital Management，Adage Capital Management LP，Pontifax和Aisling Capital以及其他医疗保健基金，Altium Capital，Amzak Health，Granite Point Capital Management，LP和LifeSci Venture参与了此次融资所有原始A系列投资者的合作伙伴和参与，包括Lumira Ventures，CAM Capital，Delos Capital，Domain Associates和Sixty Degree Capital。 Soleus Capital的合伙人David Canner和Pontifax的合伙人Iyona Rajkomar，MBBS，CFA，合伙人都将加入董事会。

Antios首席执行官Greg Mayes表示：“在我们的1b期慢性乙型肝炎患者研究中，ATI-2173已显示出有效的治疗上和持久的治疗后效果。这些结果将在即将举行的大型医学会议上发表。有了这项融资，我们现在可以继续突出显示ATI-2173如何成为HBV治疗方案的骨干，而HBV治疗仍是全球公共卫生的一项重要需求，但尚未得到满足。我们期待与新老投资者合作，推动ATI-2173的发展。”

Soleus Capital首席投资官Guy Levy说：“尽管近年来取得了长足进步，但HBV仍然是医疗需求未得到满足的领域。考虑到机械原理和令人印象深刻的早期数据，我们相信ATI-2173可能在为数百万患有慢性HBV感染的人制定治疗方案中发挥重要作用。我们很高兴与Antios经验丰富的团队合作，以帮助将这种疗法带给患者。”

关于ATI-2173
ATI-2173是一种新颖的口服肝靶向活性位点聚合酶抑制剂核苷酸（ASPIN）分子，旨在将克留夫定的5'-单磷酸酯传递至肝脏。这种L-核苷的活性5'-三磷酸酯具有独特的抗病毒特性，作为一种非竞争性，无链终止的HBV聚合酶抑制剂，会扭曲HBV聚合酶的活性位点，从而导致有效的HBV抗病毒活性和对HBV DNA的长期治疗抑制作用。 ATI-2173靶向肝脏，可提供高水平的独特5'-三磷酸酯，同时限制了对母体L-核苷的全身性暴露。 ATI-2173有可能成为慢性乙型肝炎治愈性联合疗法不可或缺的一部分。

关于Antios Therapeutics Inc.
Antios Therapeutics是一家临床阶段的生物制药公司，致力于开发治​​疗和治愈病毒性疾病的创新疗法。 Antios目前正在开发ATI-2173，旨在为慢性乙型肝炎感染患者提供治愈性联合治疗方案。

联系方式

投资者：
李·罗斯
伯恩斯·麦克莱伦（Burns McClellan）
[email protected]
+1（212）300-8331

媒体：
今井良（Ryo Imai）/罗伯特·弗拉姆（Robert Flamm）博士
伯恩斯·麦克莱伦（Burns McClellan）
[email protected] / [email protected]
+1（212）300-8315 / +1（212）300-8364